Novel compound inhibits SARS-CoV-2 replication by binding a genome target

By | July 27, 2022
Researchers assessed the biodistribution and safety of SBCoV202, a novel antiviral agent based on antisense technology that can specifically and effectively bind to the SARS-CoV-2 genome target to inhibit SARS-CoV-2 replication.